Get Live Data

The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Curevac N V Ord Share Price
  4. Curevac N V Ord Share Regulatory News

Pin to quick picksCurevac N V Ord Regulatory News (0A9E)

Curevac N V Ord Information

Share Price Information for Curevac N V Ord (0A9E)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.014
Bid: 2.864
Ask: 3.164
Change: 0.099 (3.40%)
Spread: 0.30 (10.475%)
Open: 2.974
High: 3.021
Low: 2.826
Prev. Close: 2.915
0A9E Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

12
Date   Source Headline
24th Apr 202412:08 pmEQSCureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
24th Apr 202412:04 pmEQSCureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
24th Apr 202412:01 pmEQSCureVac Appoints Thaminda Ramanayake as New Chief Business Officer
18th Apr 202412:01 pmEQSCureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
16th Apr 202412:02 pmEQSCureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
4th Apr 202412:02 pmEQSCureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
5th Jan 202412:02 pmEQSCureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
19th Dec 20232:24 pmEQSCureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
14th Nov 202312:02 pmEQSCureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
1st Nov 202312:02 pmEQSCureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
28th Sep 202312:02 pmEQSCureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
12th Sep 202312:01 pmEQSCureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
17th Aug 202312:01 pmEQSCureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
1st Aug 202312:01 pmEQSCureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
14th Jul 202312:01 pmEQSCureVac Announces Update to the Management Team
13th Jul 202312:01 pmEQSCureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
20th Jun 202312:06 pmEQSCureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
20th Jun 202312:01 pmEQSCureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
19th Jun 20234:31 pmEQSCureVac Announces Voting Results of General Meeting
30th May 202312:01 pmEQSCureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
19th May 202312:01 pmEQSCureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
8th May 202312:01 pmEQSCureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
25th Apr 202312:01 pmEQSCureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update
18th Apr 202312:01 pmEQSCureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
28th Mar 20239:06 pmEQSCureVac Announces Voting Results of Extraordinary General Meeting
10th Feb 20239:05 pmEQSCureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
8th Feb 20231:04 amEQSCureVac Announces Pricing of Upsized Public Offering of Common Shares
6th Feb 20239:06 pmEQSCureVac Announces Proposed Public Offering of Common Shares
1st Feb 202312:00 pmEQSCureVac Welcomes Myriam Mendila as New Chief Development Officer
31st Jan 20231:13 pmEQSCureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®
30th Jan 202312:02 pmEQSCureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
9th Jan 202312:00 pmEQSCureVac Appoints Alexander Zehnder as CEO From April 1, 2023
6th Jan 202312:01 pmEQSCureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs
14th Dec 20229:05 pmEQSCureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program
16th Nov 202212:00 pmEQSCureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update
11th Nov 202212:00 pmEQSCureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102
10th Nov 202212:00 pmEQSCureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022
18th Aug 202212:06 pmEQSCureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
18th Aug 202212:01 pmEQSCureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
5th Jul 202212:01 pmEQSCureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
22nd Jun 20229:05 pmEQSCureVac Announces Voting Results of General Meeting
8th Jun 20229:10 pmEQSCureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
8th Jun 20229:05 pmEQSCureVac Announces Changes of CDO - Myriam Mendila to succeed Klaus Edvardsen
25th May 202212:06 pmEQSCureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update
25th May 202212:01 pmEQSCureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
28th Apr 202212:01 pmEQSCureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update
22nd Apr 202212:01 pmEQSCureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022
21st Apr 202212:01 pmEQSCureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study
11th Apr 202212:01 pmEQSCureVac and GSK Enter into Pandemic Preparedness Contract with German Government
30th Mar 202212:01 pmEQSCureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.